Summary
A new study led by Johns Hopkins researchers found that young people with cannabis use disorder were more likely than young people with other substance use disorders to later be diagnosed with a…
Source: Business Medical Dialogues
AI News Q&A (Free Content)
Q1: What is cannabis use disorder, and how prevalent is it among young people in the United States?
A1: Cannabis use disorder (CUD), also known as cannabis addiction, is a psychiatric disorder characterized by the continued use of cannabis despite significant impairments. According to the National Survey on Drug Use and Health, nearly 7% of U.S. teens and adults met the criteria for CUD in 2024, with a prevalence rate of nearly 16% among those aged 18–25. This disorder is particularly concerning among adolescents due to their neurodevelopmental stage, often leading to poor cognitive and psychiatric outcomes, including a heightened risk of suicide attempts.
Q2: How does cannabis use disorder relate to psychiatric disorders?
A2: Cannabis use is linked to a range of mental health issues, including mood and anxiety disorders. In some individuals, it may act as a form of self-medication for psychiatric disorders. Adolescents with cannabis use disorder are at risk of poor psychiatric outcomes, and long-term cannabis use can lead to dependence in up to 9–20% of users.
Q3: What are the treatment options available for cannabis use disorder?
A3: There are currently no FDA-approved medications specifically for cannabis use disorder. Treatment often involves psychological interventions, such as cognitive behavioral therapy (CBT), motivational enhancement therapy (MET), and twelve-step programs, which have shown promise in managing cannabis dependence. Withdrawal symptoms can include irritability, anxiety, insomnia, and depression, affecting about half of those in treatment.
Q4: What recent advancements have been made in the diagnosis of psychiatric disorders using technology?
A4: Recent advancements include the development of Heart2Mind, a human-centered contestable psychiatric disorder diagnosis system using wearable ECG monitors. This system uses cardiac biomarkers to provide objective indicators of autonomic dysfunction in psychiatric conditions, offering a transparent and contestable approach to diagnosis. The system's accuracy in identifying psychiatric disorders is significantly higher than traditional methods.
Q5: How effective is N, N-dimethyltryptamine (DMT) in treating substance misuse, according to recent studies?
A5: A systematic review and meta-analysis found that DMT, a psychedelic agent, shows therapeutic potential for treatment-resistant psychiatric disorders, including substance addictions. The studies reported a large effect size for substance abuse reduction, especially when combined with psychotherapy. However, the studies had methodological limitations, and the results should be considered preliminary.
Q6: What role does Bayesian machine learning play in predicting cannabis use disorder risks?
A6: Bayesian machine learning models have been developed to predict the risks of developing cannabis use disorder in adolescence and early adulthood. These models use personal risk factors and are trained on nationally representative data, showing better predictive accuracy compared to traditional methods. This approach can help identify high-risk individuals for early intervention.
Q7: What are the common misconceptions about cannabis use disorder?
A7: A common misconception is that cannabis use disorder does not exist because cannabis is often perceived as non-addictive. However, it is a clinically recognized disorder, with significant numbers of users, particularly those with high frequency and potency of use, developing dependence.
References:
- Cannabis use disorder
- Efficacy of N, N-dimethyltryptamine (DMT) psychedelic therapy for substance misuse: A systematic review and meta-analysis.
- Heart2Mind: Human-Centered Contestable Psychiatric Disorder Diagnosis System using Wearable ECG Monitors
- A Bayesian Learning Model for Joint Risk Prediction of Alcohol and Cannabis Use Disorders
- Absolute Risk Prediction for Cannabis Use Disorder in Adolescence and Early Adulthood Using Bayesian Machine Learning
